|Dr. Michelle Miller BSc, MSc, Ph.D., GCertAppFin (Finsia)||Chief Exec. Officer, Managing Director and Exec. Director||N/A||N/A||N/A|
|Mr. Peter James Nightingale B.Econ, CA||Company Sec.||N/A||N/A||60|
|Dr. John Wilkinson Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics targeting Hepatitis C virus (HCV) and HIV-1 in Australia. Its lead antiviral drug is BIT225, a viroporin inhibitor that has completed Phase II clinical trial for the treatment of HCV, HIV, and HIV/HCV infections. The company also has various earlier stage preclinical research programs for other viral infections, including dengue. Biotron Limited is based in North Ryde, Australia.
Biotron Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.